



## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

## **Biocon Receives Approval for Antifungal Medication, Micafungin from US FDA**

***Bengaluru, Karnataka, India, June 03, 2024***

“Biocon Limited has received approval from the U.S. Food and Drug Administration (US FDA), for its vertically integrated, complex injectable drug product, Micafungin (50mg and 100mg vials), used as an antifungal medication to treat fungal or yeast infections.

The approval further strengthens Biocon’s portfolio of vertically integrated, complex drug products.”